48L.MU Stock Analysis
48
Uncovered
Beyond Air Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The company is headquartered in Garden City, New York and currently employs 70 full-time employees. The company went IPO on 2019-05-07. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are Persistent Pulmonary Hypertension of the Newborn (PPHN), community-acquired viral pneumonia (CAVP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and with various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology to generate on-demand nitric oxide from ambient air and, regardless of dose or flow, deliver it to a ventilator circuit.